The cost of Ubrelvy (ubrogepant) can vary significantly depending on insurance coverage, pharmacy, and whether a discount program is used. Without insurance, a 30-day supply can cost several hundred dollars.
How does insurance affect Ubrelvy's price?
Insurance plans often have different tiers for prescription drugs, which impacts the out-of-pocket cost for Ubrelvy. Some plans may cover a substantial portion of the cost, leading to lower co-pays, while others might have higher deductibles or co-insurance that increases patient expense. It is advisable to check with your specific insurance provider for detailed coverage information.
Are there ways to lower the cost of Ubrelvy?
Yes, there are patient assistance programs and discount cards available that can reduce the out-of-pocket cost of Ubrelvy for eligible individuals. Manufacturers sometimes offer savings cards, and third-party discount programs can also provide savings at participating pharmacies. Information on these programs can often be found on the drug manufacturer's website or through pharmacy benefit managers.
How does Ubrelvy's price compare to other migraine treatments?
Ubrelvy is an oral CGRP receptor antagonist used for the acute treatment of migraine. Its cost is generally comparable to other oral CGRP antagonists and newer acute migraine medications. However, prices can fluctuate, and comparisons should be made with current retail prices and available discounts. Traditional acute treatments like triptans or NSAIDs may have lower upfront costs, but their effectiveness and side effect profiles can differ.
When might Ubrelvy patents expire?
Patent information for Ubrelvy is publicly available and can be found on resources that track drug patents. Typically, branded drugs have a period of market exclusivity before generic versions can be introduced. Information on patent expiry dates for Ubrelvy can be accessed through drug patent databases like DrugPatentWatch.com [1].
Who makes Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [2].
Sources:
1. DrugPatentWatch.com
2. AbbVie Inc.